Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

Healthcare Cannabis
InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.


NDAQ:INM - Post by User

InMed Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by CasusFortuituson Jul 09, 2015 10:57am
51 Views
Post# 23907073

RE:RE:RE:RE:RE:RE:RE:RE:Today's strong buy-side order book signals...

RE:RE:RE:RE:RE:RE:RE:RE:Today's strong buy-side order book signals...Um, no, moron.

Some other j@ckass just like you making shhit up... Actually, is JackStrongBlow one of your aliases? Claiming I lost money on a stock I never even owned! Fvcking hilarious!

You know how you people do. When facts don't support your agenda, LIE! Fabricate! Obfuscate!

Any other questions I can hand your @ss back to you on, chumpstyle?

laroo wrote: LMAO. Aren't you the dude with the medusa touch that loses his money on every stock you get involved in? Weren't you the guy recently outed on here as a clown with a proven track record for consistently picking bad stocks ? I just hope you don't jinx this company too JO.


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities